Several studies showed that mutation or inactivation of PTEN are often associated with HER2 amplification and, as a consequence, acquired resistance to different targeted therapies, such as trastuzumab, a monoclonal antibody used in the treatment of HER2+ BC subtype, can develop. Here, ERBB2 is linked to breast cancer.